Case Study
How a client avoided $109M in pharmacy costs
New case study shows effectiveness of drug management program.
By 2023, U.S. drug spend is expected to reach up to $600 billion, with hundreds of high-cost, low-value drugs coming to market each year. Pharmacy plan sponsors can avoid unnecessary costs by spending pharmacy dollars on only the most clinically appropriate, cost-efficient medications.
Just like the state of New Jersey did.
"OptumRx has done a really great job in looking at our data and our trend and finding high-value opportunities. We're able to show our stakeholders that we are not making these changes to nickel and dime members and save $10 or $20 million here and there; we’re doing it to solve problems specific to our members." — Christin Deacon, Assistant Director of Pension and Benefits, State of New Jersey
This case study highlights how the OptumRx® Vigilant Drug ProgramTM can help.
